• SPX
  • $5,917.11
  • 0 %
  • $0.13
  • DJI
  • $43,408.47
  • 0.32 %
  • $139.53
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,121.56
  • 0.45 %
  • $36.49
  • IXIC
  • $18,966.14
  • -0.11 %
  • -$21.33
Achilles Therapeutics plc (ACHL) Stock Price, News & Analysis

Achilles Therapeutics plc (ACHL) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.07

$0.02

(1.91%)

Day's range
$1.02
Day's range
$1.07
50-day range
$0.69
Day's range
$1.12
  • Country: GB
  • ISIN: US00449L1026
52 wk range
$0.63
Day's range
$1.76


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.23
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (ACHL)
  • Company Achilles Therapeutics plc
  • Price $1.07
  • Changes Percentage (1.91%)
  • Change $0.02
  • Day Low $1.02
  • Day High $1.07
  • Year High $1.76

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/04/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $2.00
  • High Stock Price Target $2.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.60
  • Trailing P/E Ratio -0.56
  • Forward P/E Ratio -0.56
  • P/E Growth -0.56
  • Net Income $-69,665,000

Income Statement

Quarterly

Annual

Latest News of ACHL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Achilles Therapeutics plc Frequently Asked Questions

  • What is the Achilles Therapeutics plc stock price today?

    Today's price of Achilles Therapeutics plc is $1.07 — it has increased by +1.91% in the past 24 hours. Watch Achilles Therapeutics plc stock price performance more closely on the chart.

  • Does Achilles Therapeutics plc release reports?

    Yes, you can track Achilles Therapeutics plc's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Achilles Therapeutics plc stock forecast?

    Watch the Achilles Therapeutics plc chart and read a more detailed Achilles Therapeutics plc stock forecast to see what analysts suggest you do with its shares.

  • What is Achilles Therapeutics plc stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Achilles Therapeutics plc stock ticker.

  • How to buy Achilles Therapeutics plc stocks?

    Like other stocks, ACHL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Achilles Therapeutics plc's EBITDA?

    Achilles Therapeutics plc measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Achilles Therapeutics plc’s financial statements.

  • What is the Achilles Therapeutics plc's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Achilles Therapeutics plc stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Achilles Therapeutics plc's financials relevant news, and technical analysis. Achilles Therapeutics plc's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Achilles Therapeutics plc stock currently indicates a “sell” signal. For more insights, review Achilles Therapeutics plc’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.